IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+13.89%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$1B
AUM Growth
+$1B
(-1.4%)
Cap. Flow
-$24.3M
Cap. Flow
% of AUM
-2.42%
Top 10 Holdings %
Top 10 Hldgs %
47.12%
Holding
99
New
22
Increased
29
Reduced
11
Closed
29
Top Buys
| 1 |
Cytokinetics
CYTK
|
$29.8M |
| 2 |
Becton Dickinson
BDX
|
$17.5M |
| 3 |
Insmed
INSM
|
$16.8M |
| 4 |
Elevance Health
ELV
|
$16.3M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$14M |
Top Sells
| 1 |
WBA
Walgreens Boots Alliance
WBA
|
$28.2M |
| 2 |
AbbVie
ABBV
|
$24.6M |
| 3 |
Intuitive Surgical
ISRG
|
$17.8M |
| 4 |
Charles River Laboratories
CRL
|
$17.6M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$16.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Surgery Partners
SGRY
$2.89B
| $4.76M | 0.45% |
+200,000
| New | +$4.76M |
|
52
Corbus Pharmaceuticals
CRBP
$121M
| $4.53M | 0.43% |
+100,000
| New | +$4.53M |
|
|
53
Intuitive Surgical
ISRG
$158B
| $4.45M | 0.42% |
10,000
-40,000
| -80% | -$17.8M |
|
54
Catalyst Pharmaceutical
CPRX
$2.42B
| $4.26M | 0.4% |
+275,000
| New | +$4.26M |
|
55
Roivant Sciences
ROIV
$8.6B
| $4.23M | 0.4% |
400,000
-200,000
| -33% | -$2.11M |
|
56
Keros Therapeutics
KROS
$640M
| $3.88M | 0.37% |
85,000
+45,000
| +113% | +$2.06M |
|
57
Hologic
HOLX
$14.7B
| $3.71M | 0.35% |
+50,000
| New | +$3.71M |
|
58
89bio
ETNB
$1.37B
| $3.6M | 0.34% |
450,000
+150,000
| +50% | +$1.2M |
|
59
Dyne Therapeutics
DYN
$1.92B
| $3.53M | 0.34% |
+100,000
| New | +$3.53M |
|
60
Scholar Rock
SRRK
$3.3B
| $3.33M | 0.32% |
400,000
+75,000
| +23% | +$625K |
|
61
Cabaletta Bio
CABA
$144M
| $3.18M | 0.3% |
425,000
| – | – |
|
62
Editas Medicine
EDIT
$225M
| $3.15M | 0.3% |
675,000
+225,000
| +50% | +$1.05M |
|
63
Apogee Therapeutics
APGE
$2.27B
| $3.15M | 0.3% |
80,000
+40,000
| +100% | +$1.57M |
|
64
Nurix Therapeutics
NRIX
$723M
| $3.13M | 0.3% |
+150,000
| New | +$3.13M |
|
65
Fate Therapeutics
FATE
$115M
| $2.79M | 0.26% |
850,000
+650,000
| +325% | +$2.13M |
|
66
Neurogene
NGNE
$284M
| $2.55M | 0.24% |
+70,000
| New | +$2.55M |
|
67
Spyre Therapeutics
SYRE
$1.02B
| $2.35M | 0.22% |
100,000
| – | – |
|
68
Kura Oncology
KURA
$732M
| $2.06M | 0.2% |
+100,000
| New | +$2.06M |
|
|
RVNC
69
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.29M | 0.12% |
+500,000
| New | +$1.29M |
|
|
70
Regeneron Pharmaceuticals
REGN
$59.8B
| – | – |
-17,000
| Closed | -$16.4M |
|
71
Penumbra
PEN
$10.5B
| – | – |
-70,000
| Closed | -$15.6M |
|
72
Natera
NTRA
$23B
| – | – |
-50,000
| Closed | -$4.57M |
|
73
MacroGenics
MGNX
$121M
| – | – |
-500,000
| Closed | -$7.36M |
|
74
Labcorp
LH
$22.8B
| – | – |
-20,000
| Closed | -$4.37M |
|
75
Inspire Medical Systems
INSP
$2.53B
| – | – |
-33,000
| Closed | -$7.09M |
|